Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours

NCT ID: NCT07203625

Last Updated: 2026-01-22

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 506 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-20
• Study Completion Date: 2027-12-31

Brief Summary

This study is designed to investigate the efficacy and safety of intravenous tenecteplase before interhospital transfer from a non-endovascular capable center(nECC) to an endovascular capable center (ECC) for thrombectomy in patients with acute ischemic stroke (AIS) caused by neuroimaging-confirmed acute basilar artery occlusion (BAO) between 4.5-24 hours of symptom onset.

Detailed Description

This is a multicenter, prospective, open-label, blinded endpoint (PROBE), randomized controlled trial in patients with acute ischemic stroke due to BAO first presenting to a nECC and intending to undertake thrombectomy in an ECC.

Patients will be required to have occlusion of the basilar artery on baseline computed tomography angiography (CTA)/magnetic resonance angiography (MRA) at the nECC. Patients will be randomized to either intravenous tenecteplase (0.25mg/kg, maximum 25mg)or not before interhospital transfer.

Conditions

Acute Ischemic Stroke; Basilar Artery Occlusion

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Interventional group

Patients will receive intravenous Tenecteplase 0.25 mg/kg body-weight up to a maximum of 25mg before the transfer. A single bolus dose should be administered over 5-10 seconds based on patient weight. Transfer to ECCs for thrombectomy should be initiated immediately after Tenecteplase administration.

Group Type: EXPERIMENTAL

Tenecteplase thrombolysis

Intervention Type: DRUG

Patients will receive intravenous Tenecteplase 0.25 mg/kg body-weight up to a maximum of 25mg before the transfer. A single bolus dose should be administered over 5-10 seconds based on patient weight. Transfer to ECCs for thrombectomy should be initiated immediately after Tenecteplase administration.

Control group

Patients will be directly transferred to ECCs for thrombectomy according to Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Tenecteplase thrombolysis

Patients will receive intravenous Tenecteplase 0.25 mg/kg body-weight up to a maximum of 25mg before the transfer. A single bolus dose should be administered over 5-10 seconds based on patient weight. Transfer to ECCs for thrombectomy should be initiated immediately after Tenecteplase administration.

Intervention Type: DRUG

Other Intervention Names

rhTNK-tPA

Eligibility Criteria

Inclusion Criteria

• 1. Age ≥18 years; 2. Patients presenting with posterior circulation ischemic stroke symptoms due to BAO; 3. BAO confirmed by computed tomographic angiography (CTA)/ magnetic resonance angiography (MRA); 4. Time from symptom onset to randomization within 4.5-24 hours, stroke onset is defined as the time the patient was last known to be well (including wake-up stroke and unwitnessed stroke); 5. Baseline National Institute of Health Stroke Scale (NIHSS) score obtained prior to randomization ≥6; 6. Functionally independent (modified Rankin Scale [mRS] 0-2) prior to stroke onset; 7 Intended to transfer to CSCs for thrombectomy 8. Written informed consent from patients or legally responsible representatives

Exclusion Criteria

• 1 Posterior Circulation Acute Stroke Prognosis Early CT score (PC-ASPECTS) < 6 on computed tomography (CT)/CTA-Source Images/MRI with diffusion-weighted imaging (DWI) 2 CT/MR shows evidence of intracranial hemorrhage and tumor (except small meningioma) 3 Complete cerebellar infarct on CT/MRI with significant mass effect and compression of the 4th ventricle 4 Bilateral extensive brainstem infarction on CT/MRI 5 Simultaneous occlusion of both anterior and posterior circulation confirmed by CTA/MRA/DSA (patients with a history of occlusion of anterior circulation can be included) 6 Treatment with a thrombolytic within the last 72 hours or intention to receive intravenous thrombolysis 7 Known hypersensitivity or allergy to any ingredients of Tenecteplase 8 Any other contra-indication for intravenous thrombolysis except for the time criteria 9 Known hereditary or acquired hemorrhagic diathesis 10 Impairment in coagulation due to comorbid disease or anticoagulant use. If on warfarin, international normalized ratio (INR) >1.7 or prothrombin time >15s; if use of any direct oral anticoagulant within the last 48 hours; if use of heparin/heparinoid within the last 24 hours 11 Ischemic stroke or myocardial infarction in previous 3 months 12 Previous intracranial hemorrhage, active internal bleeding (gastrointestinal or urinary tract hemorrhage) in previous 3 months 13 Severe, uncontrolled hypertension (systolic blood pressure >185mmHg or diastolic blood pressure >110mmHg) 14 Baseline blood glucose <50mg/dl or >400mg/dl 15 Baseline platelet count <100,000/μL 16 Undergoing hemodialysis or peritoneal dialysis; known severe renal insufficiency with glomerular filtration rate <30mL/min or serum creatinine >220mmol/L (2.5mg/dL) 17 Known severe, life-threatening allergy (more severe than skin rash) to contrast agents 18 Patients with acute stroke within the first 48 hours after percutaneous cardiac, cerebrovascular interventions and major surgery 19 Known diagnosis or clinical suspicion of cerebral vasculitis 20 Known diagnosis or clinical suspicion of endocarditis 21 Pregnancy or lactating; 22 Other serious, advanced or terminal illness with life expectancy less than 6 months 23 Current participation in any investigational study that may confound outcome assessment of the study 24 Any condition that, in the judgement of the investigator, is inappropriate for participation in the trial or could impose hazards to the patient (e.g. inability to understand and/or follow the study procedures and/or follow-up due to mental disorders, cognitive or emotional disorders)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Xuanwu Hospital, Beijing

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Junwei Hao, MD

Role: PRINCIPAL_INVESTIGATOR

Xuanwu Hospital, Beijing

Locations

Xuanwu Hospital, Capital Medical University

Beijing, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Junwei Hao, MD

Role: CONTACT

haojunwei@vip.163.com

01083198277

Gaoting Ma, MD

Role: CONTACT

demo_doctor@163.com

01083198082

Facility Contacts

Gaoting Ma, MD

Role: primary

demo_doctor@163.com

010-83198082

Other Identifiers

XMEC-2025-003

Identifier Type: -

Identifier Source: org_study_id